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Cyclosporine A induced remission of relapsing nephrotic syndrome in
children. We treated 20, steroid resistant or steroid dependent and
cyclophosphamide or chlorambucil treated, relapsing nephrotic patients
with oral cyclosporine A for eight weeks. Cyclosporine A was started at
7 mg/kg/day and titrated to maintain HPLC level of 100 to 200 ng/ml. Of
20 patients, 14 had a complete remission and the remaining 6 had a
reduction in their proteinuria. The mean serum albumin of the 14
responders rose from 2.1 g/dl to 4.1 g/dl (P < 0.00001) after
cyclosporine A therapy. The mean serum cholesterol of the 14 respond-
ers decreased from 394 mg/dl to 184 mg/dl (P < 0.0001) after
cyclosporine A therapy. The mean creatinine clearance of the 20
patients (104 ml/min/l.73 m2) was unchanged (107 ml/min/1.73 m2) after
eight weeks of cyclosporine A. By life table analysis, 40% of the
responders show a sustained remission of up to a year. Cyclosporine A
responders had a higher T3 cell count prior to therapy compared to
nonresponders (69 5.54% vs. 61 6.4%, P < 0.02). Pre-therapy
interleukin-2 levels measured in 10 patients were normal or
supranormal in 8, 6 of whom were treatment responders. Two patients
with low interleukin-2 levels were nonresponders. Cyclosporine A can
be used to induce a remission in relapsing nephrotic patients, and
short-term cyclosporine A therapy does not produce nephrotoxicity.
The proportion of patients who will have a sustained remis-
sion of their nephrotic syndrome with the initial course of
steroid therapy is highly variable. The rates for children re-
ported in literature range from 10% in one study [1] to 60% in
another [2], and a range of 20 to 70% has been reported for
adults [31. Among those children who present with minimal
glomerular changes at initial histological study, 43% will be-
come frequent relapsers [4]; the corresponding figure for adults
is 39% [3]. Children whose disease is characterized by frequent
relapse are treated with repeated courses of steroid therapy.
When steroid toxicity develops or when the nephrotic syn-
drome develops resistance to the action of steroids, alternative
therapy consists of either cyclophosphamide or chlorarnbucil.
Based on the evidence suggesting a T cell involvement in the
pathogenesis of nephrotic syndrome [5], we have treated a
group of children whose nephrotic syndrome was either steroid
dependent or had developed steroid resistance, with a course of
cyclosporine A.
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Methods
Children between the ages of 3 and 18 years were enrolled in
the study after an informed consent was obtained from the
parents.
Criteria for entry into the study were: (1) a frequently
relapsing course, defined as two or more relapses in the
preceding six months or four or more relapses in the preceding
year; (2) steroid dependence or resistance; steroid resistance
was defined as failure to respond to 60 mg/rn2 of prednisone
given for eight weeks. Steroid dependence was defined as
recurrence of proteinuria when the dose of prednisone was
discontinued or lowered below a critical level. (3) Prior admin-
istration of at least one course of cyclophosphamide or
chlorambucil.
In patients classified as steroid dependent, prednisone was
withdrawn for 14 days prior to starting cyclosporine A therapy.
Prior to therapy, 24-hour urine protein together with serum
albumin, serum cholesterol and liver enzymes were measured.
A 24-hour creatinine clearance was obtained in all the patients
before and at the end of therapy. Additionally, (a) T cell subsets
(N = 20) (b) mitogen stimulated blast transformation (N = 20)
and (c) interleukin-2 production (N = 10) before and after
therapy were determined. T cell determination was done by
fluorescence microscopy using Ortho-mune Monoclonal Anti-
body [6]. Mitogen stimulation was measured by determining
uptake of 3H thymidine [7].
Interleukin-2 assay
Peripheral blood mononuclear cells, isolated by ficoll-hy-
paque gradient centnfugation of anticoagulated blood, were
activated with 2 g/ml of PHA. The cells were cultured for 16
hours at 37°C in a 5% of C02-95% air atmosphere and cell free
supernatants were obtained. The supernatants were screened
for IL-2 activity using an IL-2 dependent cytotoxic T cell line as
previously reported [8]. 3H-thymidine incorporation found dur-
ing 20 to 24 hours of incubation period of CTLL were deter-
mined in a liquid scintillation system and the results found with
patients cells were expressed as percent of control response
(100% = IL-2 activity found in supernatants from normal PBM
activated with PHA).
Cyclosporine A was started at 7 mg/kg/day orally in a single
dose and the dose titrated to maintain a trough HPLC whole
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Table 1. Age, sex and duration of illness prior to CY therapy
Mean Range
Age at onset 5.3 years 2—15.5
Age at the time of study 10.7 years 3—18
Duration of illness 4.8 years 6 mo—14 yrs
blood level between 100 to 200 ng/ml. Cyclosporine A dose was
reduced when the blood level was higher than 200 ng/ml, but the
dose was not increased over 7 mg/kg/day when the level of
cyclosporine A was less than 100 ng/ml. In grossly edematous
patients, prednisone was used in the dose of 5 or 10mg per day
per patient for the first 10 to 14 days. Older children received 10
mg per day and the younger ones received 5 mg per day.
Furosemide, 40 mg p.o. was also administered to edematous
patients for the first 7 to 10 days. Cyclosporine A was admin-
istered for eight weeks and then abruptly discontinued. Patients
were treated in hospital for the first three days when daily
serum creatinine was monitored. Subsequently, renal function,
liver function, serum albumin and cholesterol were measured
weekly along with quantitation of urinary protein excretion.
Student's t-test was used for paired comparisons and Fisher
exact probability test was used for observations too small to
apply a ,2 p valves below 0.05 were considered significant.
Duration of remission was calculated by actuarial methods
using the Biomedical Statistical software (Univ. of California)
series of computer program.
Results
Twenty children (13 males and 7 females) were enrolled into
the study. Table 1 shows age at onset, age at start of
cyclosporine A treatment and the duration of illness. Given the
long history of disease the number of relapses per patient were
not calculated, but an approximation of the total steroid dosage
received was made which ranged from 1.05 to 46.47 grams. Of
the 20 children, 7 were resistant to steroid therapy at the time of
entry, whereas 13 continued to be steroid sensitive but were
steroid dependent requiring continuous steroid administration
in the dose range between 20 and 40 mg/m2/day to prevent a
relapse. None of the patients classified as steroid resistant had
received bolus methyl-prednisolone therapy.
As regards prior cytotoxic therapy, one patient had received
cyclophosphamide eight weeks prior to starting cyclosporine A.
In the remaining 19 cases cytotoxic therapy had been tried at a
mean of 2.5 years prior to entry in the current study (range I to
8 years). Eight of the 20 patients were classified as cytotoxic
therapy sensitive. The seven steroid resistant patients were also
cytoxic therapy resistant.
The mean dose of cyclosporine A per patient was 6 0.5
mg/kg/day.
Remission is defined as (1) disappearance of edema, (2) urine
remaining free of protein on qualatative testing for at least three
consecutive days, and on quantitative measurement 24 hour
urine protein is less than 150 mg, (3) serum albumin greater than
2.5 g/dl, and (4) normalization of serum cholesterol.
Of 20 patients, (Nos. 1-14) Table 2, 14 achieved remission. In
addition to disappearance of proteinuria, the mean serum
albumin for these 14 patients rose from a pre-therapy level of
2.1 0.5 g/dl to 4.1 0.4 g/dl following cyclosporine A
administration (P < 0.00001). The mean serum cholesterol of
these 14 responders decreased from pre-therapy level of 394
156 mg/dl to 184 86 mg/dl after cyclosporine A administration
(P < 0.00003).
Six patients (nos. 15-20), Table 2, failed to achieve a remis-
sion, however there was reduction in proteinuria in all six
patients following cyclosporine A administration (Table 2).
Four of these six patients were steroid resistant at the time of
cyclosporine A therapy, while the remaining two were steroid
sensitive. (Fisher exact P = 0.078). The four steroid resistant
patients were cytotoxic therapy resistant as well. The other two
non-responders had responded to cytotoxic therapy in the past
with a remission of three and six months, respectively.
Of the 10 patients with focal segmental glomerulosclerosis
(Table 2), 7 were steroid resistant, and had focal segmental
sclerosis documented at the initial biopsy. The remaining three
patients had evolved from minimal change into focal segmental
sclerosis and continued to be steroid sensitive. All three steroid
sensitive and three of the seven steroid resistant patients
responded to cyclosporine A therapy. When steroid resistant
patients were separately analyzed three had a remission while
four failed to respond. The mean number of days of
cyclosporine A therapy required to produce a remission in the
responders was 21 with the earliest response being seen at
seven days and the delayed response appearing as late as 49
days.
Duration of remission
Actuarial duration of remission (Fig. 1) calculated using life
table and survival function (BMDP program) showed a 40%
sustained remission of up to one year after discontinuation of
therapy. Of 14 patients, 7 had a relapse within five months of
discontinuation of therapy, the relapse intervals being I month
(2 patients), 2 months (2 patients), 3, 4 and 5 months (I patient
each). The remaining seven patients have been in remission
from 3 to 12 months. Five of these seven patients with a
continuing remission have remained in remission for over nine
months after discontinuation of therapy. Four of these five
patients were steroid dependent requiring continued prednisone
therapy prior to entering the cyclosporine protocol. The fifth
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Fig. 1. Actuarial duration of remission in cvclosporine responders
after discontinuation of therapy.
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4+ 5234 3.6 203 29 32 0.1 4 0.8
Remission125 F.S.G.S. St.
Resistant
128
114 F.S.G.S. St. Remission
Sensitive
105
160 Mesangial St. Remission
hypercellu- Sensitive
larity
152
170 F.S.G.S. St. Remission
Resistant
166
81 1gM St. Remission
nephropathy Sensitive
80
73 F.S.G.S. St. Remission
Resistant
102
80 F.S.G.S. St. Remission
Sensitive
78
110 1gM St. Remission
nephropathy Sensitive
122
135 1gM St. Remission
nephropathy Sensitive
133
126 F.S.G.S. St. Remission
Sensitive
127
83 1gM St. Remission
nephropathy Sensitive
92
103 M.C.N.S. St. Remission
Sensitive
106
74 1gM St. Remission
nephropathy Sensitive
80
100 M.C.N.S. St. Remission
Sensitive
100
41 F.S.G.S. St. Non-responsive
Resistant to
38 cyclosporine
101 F.S.G.S. St. Non-responsive
Resistant to
98 cyclosporine
134 M.C.N.S. St. Non-responsive
Sensitive to
135 cyclosporine
124 1gM St. Non-responsive
nephropathy Sensitive to
139 cyclosporine
70 F.S.G.S. St. Non-responsive
Resistant to
76 cyclosporine
89 F.S.G.S. St. Non-responsive
Resistant to
95 cyclosporine
Table 2. Pre- and post-therapy display of all patients in the study
Urine Serum CCR
dip- 24 hour Serum choles- (ml!
S.A.
Pt. no. mm2
stick
protein
u. protein
mgiday
albumin
gm!dl
terol
mg!dISGOT SGPT
Bili-
rubin BUN
Creatin-
inea
mini
1.73 m2
Glomerular
morphology
Steroid
status
Clinical
outcome
I Pre 0.6 4+ 1722 2.2 126 31 13 0.3 36 0.5
19
3598
129
1335
4.4 88 33
2.8 404 22
4.5 164 29
2.8 293 27
Post Neg
2 Pre 1.0 4+
Post Neg
3 Pre 0.8 3+
Post Neg
4 Pre 0.8 4+
Post Neg
5 Pre 0.8 4+
Post Neg
6 Pre 0.7 4+
Post Neg7 Pre 1.1 3+
Post Neg
8 Pre 1.0 2+
Post Neg
9 Pre 1.5 3+
Post Neg
10 Pre 0.7 4+
Post Neg
11 Pre 1.0 3+
Post Neg
12 Pre 0.6 3±
Post Neg
13 Pre 0.8 4+
Post Neg
14 Pre 0.9 4+
Post Neg
15 Pre 0.9 4+
Post Trace
16 Pre 1.7 4+
Post 4+
17 Pre 0.7 4+
Post 2+
18 Pre 1.0 4+
Post 3+
19 Pre 1.5 4+
Post 2+
20 Pre 1.7 4+
<100
3892
ISO
1130
37
2876
140
3730
150
2950
140
6192
34
1120
95
1376
120
1201
6
2436
ISO
6800
120
2072
399
7693
4698
2450
1031
7308
969
2279
882
13320
4.7 133 22
1.2 630 22
4.1 231 20
2.4 402 37
4.7 128 20
2.1 279 27
4.2 134 18
2.5 266 25
4.0 198 18
1.6 498 34
4.4 128 28
1.7 642 27
4.3 182 12
2.5 319 35
4.7 163 34
2.5 381 42
4.7 169 22
2.9 299 23
3.8 219
1.8 340 32
3.6 202 39
1.2 638 18
3.2 340 19
3.7 303 24
3.9 312 23
1.8 413 20
3.5 250 15
2.3 443 14
2.3 446 18
1.6 464 24
3.4 391 31
3.6 181 18
3.7 186 18
3.3 228 14
Post
a Three values of serum creatinine per patient is shown. These are pre-, the highest during therapy and post-therapy.
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Table 3. T cell subsets and blast transformation in responders and
non-responders
Responders Non-responders P
T3 69 5.54 61 6.4 <0.02
T4 46 9.14 41 7.2 NS
T5 27.75 5.8 24.1 3.8 NS
T4/Tg 1.76 0.51 1.72 0.48 NS
PHA 29.46 19.4 27.08 20.8 NS
PWM 20.6 25.5 16.5 13.8 NS
Con A 20.54 16.2 17.03 13.2 NS
patient had steroid resistance and had been hospitalized six
times in the previous one year for albumin and lasix infusions.
Steroid dependent patients who relapsed following cyclo-
sporine therapy and required further steroid therapy, did not
achieve any diminution in their steroid dosage, but the quanti-
tative proteinuria seen was reduced by about 1/3 in 6 of the 7
patients.
T cell studies
Table 3 compares T cell subsets and blast transformation in
responders and non-responders prior to therapy. Non-respon-
ders in general had lower values in all parameters studied, but
significant differences were only noted in the T3 subset.
Interleukin studies
Of the ten patients studied, 6 of 10 patients made supranormal
amounts of IL-2, 2 of 10 made normal amounts of IL-2 and 2 of
10 made subnormal amounts of IL-2. Thus, the majority of
nephrotic syndrome patients (8 of 10) studied lacked evidence
for T cell deficiency as assessed by their ability to elaborate
IL-2. More importantly, the effectiveness of cyclosporine A
appeared to be related to the patients' lL-2 production status
prior to initiation of CSA therapy. All six patients who re-
sponded to cyclosporine A intervention made normal or
supranormal amounts of IL-2 and both patients who made
minimal IL-2 failed to respond to CSA. (Fig. 2). (x2 = 3.75, P>
0.05 = <1). The mean SE of responders was 186 30% and
the non-responders was 73 35% (t:2.02, df 8, P < 0.05, one
tail).
There was no correlation between histological involvement
and response in focal segmental glomerulo sclerosis patients.
When biopsy material was reviewed for number of focal seg-
mental lesions, degree of interstitial involvement and extent of
tubular atrophy, no differences were observed between re-
sponders and non-responders.
Side effects
There were small transient rises in serum creatinine in some
of the patients during the therapy (Table 2), but at the end of
therapy serum creatinine had returned to pre therapy values in
all but one patient who had elevated serum creatinine prior to
therapy. The mean creatinine clearance of all 20 patients
measured prior to therapy was 104 34 ml/min/1.73 m2. The
mean creatinine clearance of all 20 patients measured at the end
of cyclosporine A administration was 107 33 ml/min/1.73 m2
(P = NS). The only side effects consistently noted were minor
Patients
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Fig. 2. IL-2 activity in nephrotic syndrome patients. IL-2 activity
found in supernatants obtained from PBM from the responders (A) and
nonresponders (B) are shown. Results are expressed as percent control
(100% = IL-2 activity in supernatants from normal PBM activated with
2 g/ml of PHA).
ones of nausea and vomitting in about half of the patients, for
the first 24 to 48 hours of drug administration.
One child developed a viral pneumonia while on cyclosporine
A therapy, and one patient developed varicella one week after
initiation of cyclosporine A. Cyclosporine A was discontinued
for two weeks until the infection resolved and then was
readministered without further problem. No tremors, convul-
sions, hypertension or hyperkalemia were noted in any of the
patients.
Discussion
The therapeutic modalities presently available for patients
with frequently relapsing nephrotic syndrome are unsatisfac-
tory. Those who are steroid responsive are treated with re-
peated course of prednisolone, and prolonged maintenance
therapy is necessary for the steroid dependent patients. Com-
promise of growth is a well recognized complication of steroid
therapy, and children with a frequently relapsing course are at
high risk [9].
The pathogenesis of childhood nephrotic syndrome is un-
known, but evidence suggesting a disorder of T cell function has
been accumulating [5, 10]. A current postulate is that
lymphokines lead to alteration of glomerular anionic sites,
resulting in the increased capillary permeability to proteins [lii.
A variety of lymphokines have been identified in patients with
the nephrotic syndrome [12—141. Our presumption that
cyclosporine A might have a beneficial effect on the nephrotic
syndrome was based on the data in vitro and vivo, showing that
cyclosporine A acts by interference with lymphokine-mediated
signals between accessory cells [15—20].
The response to cyclosporine A therapy obtained in our study
can not be construed as evidence of a T cell involvement in this
disorder, since cyclosporine A has varying effects on renal
function. Studies in the animal model using both rats and dogs
has shown cyclosporine A to increase sympathetic nerve activ-
B
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ity, stimulate plasma renin activity and inhibit renal prostaglan-
din synthesis [21]. Acute and chronic administration of
cyclosporine A in rats results in increased vascular resistance
leading to decrease renal blood flow [22]. Hemodynamic alter-
ations and potential changes in glomerular filtration rates as
shown with ace inhibitor captopril can also alter the degree of
proteinuria [231. Since creatinine clearances were unaltered
following cyclosporine A therapy in our patients, it is unlikely
that the reduction in proteinuria was due to decrease in glomer-
ular filtration. Our observation that response to therapy was to
some extent related to the amount of interleukin-2 production is
interesting, but further studies in large numbers would be
necessary to document this preliminary observation. The re-
mission in one of the patients (Table 2, No. 6) occurred on the
49th day of cyclosporine A therapy, raising the question of
spontaneous remission. The evidence that this patient did not
have a spontaneous remission is based on his subsequent
course. This patient remained in remission for three months
after discontinuation of therapy. He received monthly courses
of bolus methyl prednisolone and albumin infusion over the
next five months. Subsequently he received a second course of
cyclosporine A and went into remission during the course of
therapy.
Low-dose cyclosporine therapy utilized in this study was
based on observations in renal transplant recipients converted
to cyclosporine [24]. While this dosage regimen did not lead to
nephrotoxicity in our study patients, the failure of a third of
patients to obtain remission of their nephrotic syndrome may be
related to inadequate dosage. Despite our inability to induce a
remission in these patients, the reduction in the proteinuria
produced by a course of cyclosporine A in these patients is
beneficial since the injurious nature of heavy proteinuria to the
kidney has recently been documented [25].
The use of cyclosporine A for the treatment of nephrotic
syndrome in children and adults has been reported in small
studies with differing results. Thus, Meyrier et at [Ill in six
adult patients obtained a remission in three minimal change
nephrotic syndrome patients, but only a partial remission in
three, focal-segmental glomerulosclerosis patients. On the basis
of their incomplete response in the steroid resistant cases, the
authors suggest that minimal change nephrotic syndrome and
focal segmental glomerulosclerosis may be different entities.
However, the inability to obtain a complete remission in the
focal segmental glomerulosclerosis patients may be related to
the initial lower dose employed in their study. Capodicasa et al
[26], on the other hand, using a 150 mg/rn2 dose did achieve a
remission in two of the four steroid-resistant cases, and overall
5 of their II patients remain in sustained remission after
discontinuation of cyclosporine A. Similarly, Brandis et at [271
observed complete remission in four steroid-resistant patients
after a short course of cyclosporine A given in the dose of 100
to 300 mg/m2. Niaudet et at [28] treated 10 steroid-resistant
children using a 6 mg/kg dose and obtained partial remission in
three, complete remission in one and failure to remit in six.
Eight steroid-sensitive patients in the same study had complete
remission.
The results from these small studies taken together with our
uncontrolled study seem to suggest that patients with a steroid-
responsive nephrotic syndrome have a reasonable potential for
undergoing a remission with cyclosporine A. The ability of
cyclosporine A to duplicate the efficacy of steroids is probably
related to the similarities of action between these two drugs
[29]. The duration of remission following cyclosporine A ther-
apy, however, seems to vary in different studies, and
cyclosporine A dependence has been suggested by some inves-
tigators [30]. The data regarding steroid resistant patients seems
conflicting and a controlled trial in steroid-resistant focal seg-
mental glomerulosclerosis patients is necessary to determine
the dose and duration which may lead to a remission, if any.
Such a controlled trial would be appropriate since the prognosis
in children with focal segmental glomerulosclerosis whose
nephrotic syndrome is steroid resistant, is unfavorable [3 1—33].
The relative absence of the well-known side effects of
cyclosporine A in our study is obviously related to the short
duration of therapy. Others, however, using the drugs for
longer periods have noted gum hyperplasia, hypertrichosis and
hypertension [28]. Hyperkalemia, gingival hyperplasia and
hirsuitism were also noted by Capodicasa et at [26] using the
drug for six months. Thus long term tolerance of cyclosporine A
in nephrotic syndrome patients remains to be evaluated, and
careful monitoring of both blood levels and clinical markers of
toxicity is mandatory in all patients receiving cyclosporine A
for their relapsing nephrotic syndrome.
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